Michael Bzorek

Jun 13, 2024 | biorxiv.org | Matthias Mann |Xiang Zheng |Lars Pedersen |Michael Bzorek

AbstractCoexistence of two cancer types in the same organ presents challenges for clinical decision-making, calling for personalized treatment strategies. Deep Visual Proteomics (DVP) combines AI driven single cell type analysis with laser microdissection and ultrasensitive mass spectrometry. In a composite case of classical Hodgkin lymphoma (cHL) and small lymphocytic lymphoma (SLL) in a single patient, we investigated the potential of DVP to inform precision oncology.